Strategic Plan 2019
Our latest strategic plan is built on three pillars — Immunotherapy, Investment, and Democratization of Care. Targeting our efforts in these three areas will transform how multiple myeloma is treated and ultimately cured.
Over the past year, the MMRF team has performed a comprehensive analysis of the research landscape. We’ve carefully studied every drug and research portfolio in the field of myeloma. We’ve consulted with the best and brightest clinicians, researchers, pharmaceutical companies, and data experts. Most importantly, we’ve listened to myeloma patients and we’ve heard every idea they have about how to improve their care and every hope they have for today and for their futures.
The result is an innovative new strategic plan with profound potential to revolutionize how multiple myeloma is treated and eventually cured. The plan is built on three critical pillars. Together, they will enable us to usher in a new era of discoveries that will deliver the breakthrough treatments patients deserve.
Our plan focuses on three critical areas:
Immunotherapy. Immunotherapy is a collection of approaches that trains and directs the body’s natural immune system to attack cancer cells. In the last few years alone, more than 2,000 new immunotherapy agents have entered development. Unfortunately, few are focused on multiple myeloma. The ones that are don’t work for every patient. We are focusing on several specific types of immunotherapy that show promise for myeloma, including chimeric antigen receptor T-cell (CAR-T) therapy, vaccines, and monoclonal antibodies. Read more.
Investment. Multiple myeloma is an incredibly diverse disease at the genetic level. Because every patient is different, we will need a multitude of drugs to effectively treat and cure every patient. We created the Myeloma Investment Fund and funded it with more than $10 million in seed capital to support and attract new cutting-edge partners to the field. By investing in and partnering with young companies developing promising therapies, we will accelerate new treatments while generating funding for even more research. Read more.
Democratization of Care. Each day, patients call us asking what treatment is right for their specific myeloma subtype. The answer lies in the data. On June 12, we launched the MMRF CureCloud®, a robust, comprehensive database of genetic, immune, and clinical data from myeloma patients. This state-of-the-science resource will allow us to develop data-driven, patient-specific treatment plans. Patients will soon be able to share their data in the CureCloud. Researchers and clinicians will use that data to learn in real time and make discoveries that will lead to longer, healthier lives. Read more.